Skip to main content
Femtobiomed Inc. logo

Femtobiomed Inc. — Investor Relations & Filings

Ticker · 327610 ISIN · KR7327610002 KO Professional, scientific and technical activities
Open in API
Filings indexed 201 across all filing types
Latest filing 2025-06-18 Director's Dealing
Country KR South Korea
Listing KO 327610

About Femtobiomed Inc.

https://www.femtobiomed.com/

Femtobiomed Inc. is a cell engineering company that develops technologies for the cell and gene therapy industry. The company's core offering is the CellShot® platform, a proprietary, non-viral intracellular delivery system. This platform utilizes a patented technology known as 'Partitioned Flow Transfection,' which functions as a three-dimensional nanoinjection system for the direct, cargo-free delivery of biomolecules into individual cells. The technology is designed to support the discovery and development of advanced therapeutics, including anti-cancer treatments, for the healthcare and research sectors. Femtobiomed aims to pioneer non-viral cell engineering to accelerate the creation of novel cell therapies.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details share acquisitions (장내매수) by an executive (CEO Lee Sang-hyun) of FemtoBiomed. This type of filing is a standard disclosure for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2025-06-18 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of an executive (Lee Sang-hyun) of FemtoBiomed, including specific dates of '장내매수' (on-market purchases). This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2025-06-16 Korean
기업설명회(IR)개최결과
Regulatory Filings Classification · 1% confidence The document is a short, structured announcement (934 characters) reporting the results of an Investor Relations (IR) event held by FemtoBioMed. It provides details on the date, location, participants, and content of the meeting, and explicitly states where the IR materials are posted. Since it is an announcement of an event and the availability of materials rather than the presentation itself, it falls under the category of a Report Publication Announcement or general regulatory filing. Given the specific nature of reporting the outcome of an IR event, it is best classified as a Report Publication Announcement (RPA).
2025-06-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of a specific individual (Lee Sang-hyun, CEO) in the company FemtoBiomed. This type of filing is a standard regulatory requirement for insider shareholding disclosures, which corresponds to the 'Director's Dealing' category.
2025-06-09 Korean
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities. It details specific share transactions (insider trades) by an executive (Lee Sang-hyun) of Femto BioMed. This type of filing is classified as 'Director's Dealing' (DIRS) as it reports personal share transactions by company directors and executives.
2025-06-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details share transactions (acquisitions) by an executive (Lee Sang-hyun) of FemtoBiomed. This type of filing is a standard regulatory requirement for insider trading/shareholding disclosures, which corresponds to the 'Director's Dealing' category.
2025-06-09 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.